In vitro Anti-HIV-1 Activity of sn-2-Substituted 1-O-Octadecyl-sn-Glycero-3-Phosphonoformate Analogues and Synergy with Zidovudine

Monoalkyl ether lipid analogues of foscarnet (phosphonoformate, PFA) exhibit substantially greater in vitro antiviral activity than unmodified PFA against human immunodeficiency virus type 1 (HIV-1). Our previous studies indicate that the length of the alkyl chain must be 14–22 carbons for optimal antiviral activity. To further evaluate the structure-activity relationship, we prepared 1-O-octadecyl-sn-glycerol analogues of PFA with various substitutions at the sn-2 position of glycerol and determined the effect of structure on in vitro antiviral activity and selectivity against HIV-1 in MT-2 and CD4-expressing HeLa cells (HT4–6C). We also studied combinations of zidovudine with PFA, 1-O-octadecyl-2-O-methyl-sn-glycero-3-PFA, or 1-O-octadecyl-sn-glycero-3-PFA and calculated their combination index values against HIV-1 in HT4–6C cells. Alkyl substitutions of one to four carbons at the sn-2 position of glycerol showed optimal antiviral activity. Both alkyl ether lipid analogues were strongly synergistic with zidovudine over a wide range of drug ratios and concentrations. 1-O-octadecyl-sn-glycerol analogues of PFA have selective antiviral properties and warrant further evaluation as potential antiretroviral drugs.

[1]  K. Abromeit.  Music Received , 2023, Notes.

[2]  C. Piantadosi,et al.  Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/gp120 binding to monoclonal antibody. , 1995, AIDS research and human retroviruses.

[3]  R. Schinazi,et al.  Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro , 1989, Antimicrobial Agents and Chemotherapy.

[4]  D. Richman,et al.  Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. , 1996, Antiviral research.

[5]  M. Jacobson,et al.  Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. , 1988, The Journal of infectious diseases.

[6]  J. Mellors,et al.  Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1. , 1995, Virology.

[7]  D. Richman,et al.  Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV. , 1997, Antiviral research.

[8]  Short Communication: Impaired Fitness of Foscarnet-Resistant Strains of Human Immunodeficiency Virus Type 1 , 1998 .

[9]  K. Aldern,et al.  Alkylthioglycerol Prodrugs of Foscarnet: Synthesis, Oral Bioavailability and Structure–Activity Studies in Human Cytomegalovirus-, Herpes Simplex Virus Type 1- and Human Immunodeficiency Virus Type 1-Infected Cells , 1998, Antiviral chemistry & chemotherapy.

[10]  C. Piantadosi,et al.  Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation. , 1990, AIDS research and human retroviruses.

[11]  G. D. Kini,et al.  Synthesis and antiviral activity of 1-O-octadecyl-2-O-alkyl-sn-glycero-3-foscarnet conjugates in human cytomegalovirus-infected cells. , 1997, Antiviral research.

[12]  M. Pallavicini,et al.  Synthesis and Ruthenium-Catalyzed Enantioselective Hydrogenation of 3-O-Substituted 1,3-Dihydroxypropan-2-ones. Part 2† , 1993 .

[13]  M. Jacobson,et al.  Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. , 1992, The Journal of infectious diseases.

[14]  J. Mellors,et al.  Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet , 1996, Journal of virology.

[15]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[16]  E. Arnold,et al.  Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates , 1995, Antimicrobial agents and chemotherapy.

[17]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[18]  A. So,et al.  Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Balfour,et al.  Foscarnet for suppression of human immunodeficiency virus replication , 1994, Antimicrobial Agents and Chemotherapy.

[20]  B. Gazzard,et al.  Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex. , 1987, AIDS.

[21]  J. Mills,et al.  Coresistance to Zidovudine and Foscarnet Is Associated with Multiple Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 1998, Antimicrobial Agents and Chemotherapy.

[22]  S. Clissold,et al.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. , 1991, Drugs.